4D Molecular Therapeutics shares are trading lower. Leerink Partners lowered its price target on the stock from $40 to $36.
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics shares are experiencing a decline after Leerink Partners reduced its price target from $40 to $36.
September 19, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
4D Molecular Therapeutics shares are trading lower following a price target reduction by Leerink Partners from $40 to $36.
The reduction in price target by Leerink Partners is likely to negatively impact investor sentiment, leading to a short-term decline in FDMT's stock price. The price target cut suggests a less optimistic outlook on the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100